Introduction
studies, including pp65 [7] , and anti-CMV IgM were performed. Although both were negative, a presumptive Infectious complications remain one of the major diagnosis of CMV reactivation on clinical grounds was problems after renal transplantation [1] . With the made and intravenous ganciclovir therapy was instituted recent use of more potent immunosuppressive drug (3.0 mg/kg twice daily). Within 36 h the fever resolved. regimens, such as the combination of cyclosporin Intravenous ganciclovir was stopped after 10 days. (CsA), prednisone and mycophenolate mofetil Unfortunately, two days later the patient again (MMF ), the incidence of acute rejection after renal developed fever (38.5°C ), this time accompanied by transplantation can be reduced. The incidence of clinicdiffuse abdominal pain, nausea and bloody diarrhoea. ally important cytomegalovirus (CMV ) disease how-No period of hypotension was observed. A colonoscopy ever is increased in patients treated with this triple reaching halfway along the descending colon was perdrug regimen [2] [3] [4] . Clinically important CMV colitis formed. The rectum and sigmoid showed the features primarily due to vasculitis, a clinical entity well known of a severe ischemic colitis with submucosal haemorin patients with AIDS, has been uncommon in renal rhage and oedema without ulceration ( Figure 1 ). In the transplant recipients in the last 10 years [5, 6 ] . We descending colon a patchy vasculitis was present with describe a renal transplant patient, seropositive for slight oedema of the surrounding mucosa. The endos-CMV prior to transplantation, with CMV vasculitis of copic aspect was consistant with either an ischaemic the colon, with an endoscopic image commonly associ-colitis or a vasculitis due to CMV, several biopsies were ated with ischaemic colitis.
taken. A Doppler ultrasound of the abdominal arteries showed no thrombosis or dissection. Because of a strong suspicion of CMV colitis, therapy with ganciclovir was
Case report
reinstituted, which resulted in a complete clinical recovery after 3 days. A repeated pp65 titer as well as an A 50-year-old Somalian man, with renal insufficiency IgM anti CMV remained negative. Stool cultures, due to hypertension, received his first cadaveric renal including two Clostridium difficile toxin assays were transplantation 1 month prior to admission. He was negative. Pathological examination of the colon biopsies treated with CsA (150 mg b.i.d.), prednisone revealed cytomegalovirus colitis. Inclusion bodies were (10 mg/day) and MMF (2 g b.i.d.) as immunosuppres-found mainly in cells located in the wall or lining the sive therapy. No induction therapy was given. The lumen of submucosal blood vessels, showing features of recipient was CMV seropositive prior to transplanta-vasculitis (Figure 2) , and occasionally in epithelial cells. tion. On admission the patient complained of general The diagnosis was confirmed immunohistochemically malaise and spiking fever (40°C ) since 2 days, occurring (Figure 3) . predominantly in the morning. At physical examination no abnormalities, except fever, were found. Laboratory Discussion complications. A new immunosuppressive drug, mycophenolate mofetil, has entered the scene in renal transplantation. The safety and efficacy of mycophenolate mofetil after renal transplantation has been studied in three large, double blind, controlled trials [2] [3] [4] . There is a higher risk for CMV disease in patients using MMF compared to control groups treated with placebo or azathioprine [8] . Our patient shows a severe reactivation of a CMV infection, resulting in a tissue invasive CMV vasculitis of the colon, with an ischaemic colitis. Surprisingly, on both occasions no CMV-IgM could be detected. One might speculate whether this was the result of impaired antibody production during this very severe CMV infection [9] , or due to a diminished antibody production related to MMF [10] . The results of pathological examination of the colon biopsies make the diagnosis of tissue invasive CMV certain. The lesson to be learned from this CMVseropositive patient developing CMV colitis after transplantation, is that the risk of CMV disease in patients being treated with MMF is increased and that the invasive forms. Furthermore, a high clinical suspicion for CMV disease and biopsies were necessary for prompt recognition and treatment in this patient, as customary screening methods for CMV disease remained negative. Most importantly however, clinicians must be aware of this increased risk, enabling them to respond adequately to cases like our patient.
